TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, ther...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Tenshin, Hirofumi, Teramachi, Jumpei, Oda, Asuka, Amachi, Ryota, Hiasa, Masahiro, Bat-Erdene, Ariunzaya, Watanabe, Keiichiro, Iwasa, Masami, Harada, Takeshi, Fujii, Shiro, Kagawa, Kumiko, Sogabe, Kimiko, Nakamura, Shingen, Miki, Hirokazu, Kurahashi, Kiyoe, Yoshida, Sumiko, Aihara, Kenichi, Endo, Itsuro, Tanaka, Eiji, Matsumoto, Toshio, Abe, Masahiro
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Immunobiology and Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737122/
https://ncbi.nlm.nih.gov/pubmed/29296860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017008813
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars